Login
Companies $XBIO
$1.49 -$0.17 (10.24%) Close
Xenetic Biosciences, Inc. logo

Xenetic Biosciences, Inc.

xeneticbio.com

What Do They Do?

Develops DNase technology for use alongside cancer treatments for patients with pancreatic and other solid tumors, and licenses its PolyXen drug-delivery platform to pharmaceutical and biotechnology companies.

How Do They Make Money?

Partners pay for licenses and collaboration work through upfront fees and development or regulatory milestones; royalties are tied to partner product sales and earned in the period of sale, while some license payments are spread over service periods.

FY2025 revenue

Who Are Their Customers?

Pharmaceutical and biotechnology companies work with Xenetic through supply, license and collaboration arrangements; Serum Institute holds an exclusive PolyXen license, with royalties tied to sales to its customers in its territory.

Do Revenues Turn Into Profits?

No. It lost $2.7M in FY2025.

Operating income, FY2025
−95% of revenue
▲ +33% (Loss) vs FY2024 (−$4.2M, −168%)
Net income, FY2025
−90% of revenue
▲ +32% (Loss) vs FY2024 (−$4M, −158%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −29%
vs $1M in Q3 FY2025
Net income
▼ −232% (Loss)
vs −$509.9K in Q3 FY2025
  • Nov 13, 2026 Announced a proposed acquisition of Santersus The all-stock transaction remains subject to Xenetic stockholder approval and other closing conditions.

Growing. Revenue grew 2.6x in 4 years, from $1.2M in FY2021 to $3M in FY2025, about 27% a year.

Who Do They Compete With?

Competes with Merck

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support